SAN DIEGO, April 22 Cardium Therapeutics(Amex: CXM) and its operating unit InnerCool Therapies announced today thatInnerCool's endovascular Celsius Control System will be featured on ScienceChannel's "Cool Stuff: How It Works" series. The segment (episode 5) willfeature InnerCool's endovascular cooling during a 6-hour brain surgery and isscheduled to air on Friday, April 25, 2008 at 8:00 p.m. (ET/PT). Please visithttp://science.discovery.com/tv-schedules/series.html for broadcast dates andtimes in your area.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc.and the Tissue Repair Company, are medical technology companies primarilyfocused on the development, manufacture and sale of innovative therapeuticproducts and devices for cardiovascular, ischemic and related indications.Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec,Ad5FGF4), is a DNA-based growth factor therapeutic being developed forpotential use by interventional cardiologists as a one-time treatment topromote and stimulate the growth of collateral circulation in the hearts ofpatients with ischemic conditions such as recurrent angina. For moreinformation about Cardium and its businesses, products and therapeuticcandidates, please visit http://www.cardiumthx.com or view its 2006 AnnualReport at http://www.cardiumthx.com/flash/pdf/2006CardiumAnnualReport.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medicaltechnology company in the emerging field of patient temperature modulationtherapy to rapidly and controllably cool the body in order to reduce celldeath and damage following acute ischemic events such as cardiac arrest orstroke, and to potentially lessen or prevent associated injuries such asadverse neurological outcomes. For more information about Cardium's InnerCoolsubsidiary and patient temperature modulation, including InnerCool's CelsiusControl System(TM), which has received regulatory clearance in the U.S.,Europe and Australia, please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-basedbiopharmaceutical company focused on the development of growth factortherapeutics for the treatment of severe chronic diabetic wounds. TRC's leadproduct candidate, Excellarate(TM), is a DNA-activated collagen gel fortopical treatment formulated with an adenovector delivery carrier encodinghuman platelet-derived growth factor-BB (PDGF-BB). Excellarate is initiallybeing developed to be administered once or twice for the potential treatmentof non-healing diabetic foot ulcers. Other potential applications for TRC'sGene Activated Matrix(TM) (GAM(TM)) technology include therapeuticangiogenesis (cardiovascular ischemia, peripheral arterial disease) andorthopedic products, including hard tissue (bone) and soft tissue (ligament,tendon, cartilage) repair. For more information about Cardium's Tissue RepairCompany subsidiary, please visit http://www.t-r-co.com.
Except for statements of historical fact, the matters discussed in thispress release are forward looking and reflect numerous assumptions and involvea variety of risks and uncertainties, many of which are beyond our control andmay cause actual results to differ materially from stated expectations. Forexample, there can be no assurance that commercialization efforts willeffectively accelerate InnerCool's patient temperature modulation business,that product modifications or launches will be successful or that theresulting products will be favorably received in the marketplace, that ourproducts or proposed products will prove to be sufficiently safe andeffective, that our products or product candidates will not be unfavorablycompared to competitive products that may be regarded as safer, moree